Form 6-K Calliditas Therapeutics For: Jul 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St starts the month strong as Mideast deal hopes rise
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Calliditas Therapeutics AB (CALT) Gains on EU Licensing Deal
July 21, 2021 10:26 AM EDTOn July 21st, 2020, Calliditas Therapeutics AB (NASDAQ: CALT) announced that it has entered into a licensing agreement with STADA Arzneimittel AG ("STADA") for EU commercialization of Nefecon CALTs novel drug candidate with the potential to become the first EU approved treatment for Bergers disease.
Under the terms of the agreement, Calliditas is entitled to receive an initial upfront payment of 20M EUR ($24m) upon signing and up to an additional 77.5M EUR ($91m) in future... More
